Overview
- The company is slated to report fourth-quarter and full-year 2025 results on Thursday, Feb. 12.
- Shares have underperformed over the past year, hovering roughly flat and trailing the broader market.
- In the third quarter, revenue rose 11% to $3.08 billion and EPS increased 4.7% to $4.20 as higher R&D spending tempered profit growth.
- The stock fell after the last earnings update, with selling attributed to underwhelming sales of some newer therapies.
- Vertex remains the leader in cystic fibrosis and recently gained approvals for Casgevy and Journavx, while 2025 revenue was guided to $11.9 billion to $12.0 billion and uptake of the new products remains a key watch item.